These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 6996209)

  • 1. Decreased plasminogen activator but normal prostacyclin activity in rat veins during development of experimental thrombosis.
    Mysliwiec M; Villa S; Kornblihtt L; de Gaetano G; Donati MB
    Thromb Res; 1980 Apr 1-15; 18(1-2):159-65. PubMed ID: 6996209
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pharmacologic aspects of thrombophilia].
    Markwardt F
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(4):535-49. PubMed ID: 6083924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Release of prostacyclin into the bloodstream and its exhaustion in humans after local blood flow changes (ischemia and venous stasis).
    Serneri GG; Masotti G; Poggesi L; Galanti G
    Thromb Res; 1980 Jan 1-15; 17(1-2):197-208. PubMed ID: 6990547
    [No Abstract]   [Full Text] [Related]  

  • 4. [Clinical significance of the fibrinolysis system].
    Himmelreich G; Riess H
    Dtsch Med Wochenschr; 1991 Mar; 116(11):426-30. PubMed ID: 1900466
    [No Abstract]   [Full Text] [Related]  

  • 5. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor.
    Nilsson IM; Ljungnér H; Tengborn L
    Br Med J (Clin Res Ed); 1985 May; 290(6480):1453-6. PubMed ID: 3922531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Role of the initial level of plasminogen activator in changes in fibrinolysis].
    Andreenko GV; Liutova LV; Karabasova MA; Podorol'skaia LV; Serebriakova TN
    Fiziol Zh SSSR Im I M Sechenova; 1983 Mar; 69(3):380-5. PubMed ID: 6343132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Decreased fibrinolytic activity in venous walls of patients with venous thromboses].
    Hach V; Heyland H; Walter-Fincke R; Scharrer I
    Vasa; 1985; 14(4):336-9. PubMed ID: 4072368
    [No Abstract]   [Full Text] [Related]  

  • 8. Venous thrombosis in a family with defective release of vascular plasminogen activator and elevated plasma factor VIII/von Willebrand's factor.
    Stead NW; Bauer KA; Kinney TR; Lewis JG; Campbell EE; Shifman MA; Rosenberg RD; Pizzo SV
    Am J Med; 1983 Jan; 74(1):33-9. PubMed ID: 6401391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Disorders in the release of plasminogen activators].
    Brommer EJ
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(1-2):198-207. PubMed ID: 2427402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Coagulation physiological findings in thrombosis].
    Nilsson IM; Cronberg S
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1975; 102(2):124-9. PubMed ID: 50976
    [No Abstract]   [Full Text] [Related]  

  • 11. Prostacyclin is a circulating hormone.
    Moncada S; Korbut R; Bunting S; Vane JR
    Nature; 1978 Jun; 273(5665):767-8. PubMed ID: 351418
    [No Abstract]   [Full Text] [Related]  

  • 12. Fibrinolytic and antithrombotic action of bromelain may eliminate thrombosis in heart patients.
    Felton GE
    Med Hypotheses; 1980 Nov; 6(11):1123-33. PubMed ID: 6256612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced prostacyclin activity in systemic lupus erythematosus.
    McVerry BA; Machin SJ; Parry H; Goldstone AH
    Ann Rheum Dis; 1980 Oct; 39(5):524-5. PubMed ID: 7002067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Local plasminogen activator and prostacyclin-like activity after partial venous occlusion--an experimental study in the dog.
    Andrade JA; Monteiro AC; Adolfo A; Cabral JM
    Thromb Res; 1988 Jul; 51(1):45-54. PubMed ID: 3046044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet adhesion and aggregation in arteries of rats, rabbits and guinea pigs in vivo and in vitro correlate negatively with their prostacyclin (PG I2) production.
    Tschopp TB; Baumgartner HR
    Agents Actions Suppl; 1979; (4):156-62. PubMed ID: 386741
    [No Abstract]   [Full Text] [Related]  

  • 16. [A family with reduced plasminogen activator activity in the blood associated with recurrent thrombosis].
    Jørgensen M; Mortensen JZ; Madsen AG; Thorsen S; Jacobsen B
    Ugeskr Laeger; 1983 Jul; 145(30):2302-3. PubMed ID: 6685363
    [No Abstract]   [Full Text] [Related]  

  • 17. Prostacyclin in pregnancy.
    Lewis PJ; Boylan P; Friedman LA; Hensby CN; Downing I
    Br Med J; 1980 Jun; 280(6231):1581-2. PubMed ID: 7000245
    [No Abstract]   [Full Text] [Related]  

  • 18. Measurement of circulating prostacyclin.
    Haslam RJ; McClenaghan MD
    Nature; 1981 Jul; 292(5821):364-6. PubMed ID: 7019720
    [No Abstract]   [Full Text] [Related]  

  • 19. Stability of prostacyclin in plasma.
    Jørgensen KA; Stoffersen E; Dyerberg J
    Lancet; 1979 Jun; 1(8130):1352. PubMed ID: 87815
    [No Abstract]   [Full Text] [Related]  

  • 20. Microvascular disease and limited joint mobility in diabetes. A comparison of fibrinolysis and prostacyclin in diabetes and systemic sclerosis.
    Larkin JG; Belch JJ; Flanigan P; Forbes CD; Frier BM
    Diabet Med; 1988 Jan; 5(1):53-6. PubMed ID: 2964329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.